Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
461-480 of 1,694 trials

Advanced Head and Neck Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for adults with advanced head and neck cancer who have recently completed chemoradiotherapy without surgery. This trial compares the treatment to observation to see which approach may help patients more.

Unresected Locally Advanced Head and Neck Squamous Cell CarcinomaConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOtolaryngology

Plaque Psoriasis in Teens: Deucravacitinib Study

We are evaluating a new medication for adolescents with moderate to severe plaque psoriasis to see if it helps improve their skin condition compared to a placebo. The study also looks at safety and how patients feel about their treatment.

Plaque Psoriasis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Radiprodil for Seizures in Tuberous Sclerosis and Focal Cortical Dysplasia

We are studying the safety and effects of radiprodil on seizures and behavior in patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II. This research may help improve treatment options for these conditions.

Focal Cortical Dysplasia (FCD)Tuberous Sclerosis Complex (TSC)3-6 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Melanoma Treatment: Pembrolizumab with New Agents

We are studying the safety and effectiveness of pembrolizumab alone or with new investigational treatments for people with melanoma. This research aims to find better options for managing this type of skin cancer.

Melanoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Major Depressive Disorder: NMRA-335140 Study

We are testing a new oral medication for adults with major depressive disorder to see if it helps improve their symptoms compared to a placebo. The study will measure changes in mood and daily functioning over six weeks.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Tourette Disorder: Serotonin and Impulsivity Study

We are investigating how serotonin receptors relate to impulsivity in adults with Tourette's syndrome. This study may help us understand brain activity and behavior during treatment.

Tourette Syndrome>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPsychiatry

Advanced Urothelial Carcinoma: MK-2870 with Enfortumab Vedotin

We are studying a new treatment combining MK-2870 with Enfortumab Vedotin and Pembrolizumab for patients with advanced bladder cancer. The goal is to assess safety and how well it works compared to existing options.

Bladder Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Chronic Lymphocytic Leukemia: New Triple Therapy Study

We are testing a new combination of medications for patients with high-risk chronic lymphocytic leukemia who haven't been treated before. The study aims to see if this new treatment can help keep the disease from progressing better than standard options.

High-Risk Hematological Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Chronic Kidney Disease: FINESSE Study on Albuminuria Reduction

We are researching how well finerenone and semaglutide can lower albuminuria in patients with chronic kidney disease. The goal is to find the most effective treatment for each individual and explore remote monitoring options.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyNephrology

Chronic Kidney Disease: Baxdrostat with Dapagliflozin

We are studying whether the combination of baxdrostat and dapagliflozin is more effective than dapagliflozin alone for adults with chronic kidney disease and high blood pressure. The trial will assess its impact on kidney health and heart-related risks.

Chronic Kidney DiseaseHypertension>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineNephrology

Repotrectinib for Advanced Cancers in Kids and Young Adults

We are studying a new treatment for children and young adults with advanced cancers that have specific genetic changes. The trial aims to evaluate how well it works and its safety.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Fasudil for Early Alzheimer's Disease

We are studying whether fasudil can help prevent memory loss in people with early Alzheimer's disease. The trial will also assess its safety and effects on brain health.

Alzheimer's DiseaseCognitive ImpairmentEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Parkinson's Disease: AAV2-GDNF Treatment Study

We are studying a new therapy to see if it can improve motor symptoms in adults with moderate Parkinson's Disease. The trial also looks at safety and overall quality of life for participants.

Parkinson's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurology

Propranolol for Anxiety in Pancreatic Cancer Surgery

We are studying whether propranolol can help reduce anxiety in patients undergoing surgery for pancreatic cancer and if it affects tumor-related changes. This trial will compare the effects of propranolol to a placebo in a small group of participants.

Pancreatic Cancer>2 yearsEfficacy phase (II)Standard MedicinesGastroenterologyInternal MedicineOncology

Mycobacterium abscessus: Optimizing Lung Disease Treatment

We are studying the best treatment options for lung disease caused by Mycobacterium abscessus. Our goal is to see how well these treatments clear the infection and how well patients tolerate them.

Mycobacterium Abscessus Infection1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesPulmonology

Acute Leukemia: Bleximenib Study

We are testing a new drug called Bleximenib for people with acute leukemia to find the best dose and check its safety. We also want to see if it helps improve treatment outcomes.

Acute Leukemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematology

Acute Myeloid Leukemia: Bleximenib Treatment Study

We are testing a new drug, bleximenib, combined with current therapies for patients with acute myeloid leukemia who have certain genetic changes. The goal is to find the best dose and ensure it is safe for use.

Acute Myeloid Leukemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Severe Depression: Ketamine vs. Placebo

We are studying whether adding ketamine to venlafaxine helps hospitalized patients with severe depression feel better faster than a placebo. We’re also looking at its effects on hospital stay and side effects.

Major Depressive Disorder1-2 yearsConfirmation phase (III)Investigational MedicinesPsychiatry

Liver Transplant: Single vs. Twice Daily Immunosuppressive Doses

We are studying whether a single daily dose of immunosuppressive medication is as effective as a twice-daily dose for liver transplant recipients. This trial also compares two different formulations of tacrolimus to see which works better.

Transplantation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHepatologyInternal Medicine

Schizophrenia: Intensified Treatment Study

We are investigating whether a six-week intensified medication plan helps individuals with schizophrenia who didn't respond to their first treatment. The study looks at changes in symptoms, functioning, and overall well-being compared to standard care.

Schizophrenia and Related Disorders≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry